NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
30 mars 2023 08h40 HE
|
NurExone
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing...